CAN14

CAN14 is a preclinical bispecific antibody being developed by Cantargia, a Swedish biotechnology company. It is the newest project emerging from the company's CANxx platform, which focuses on the Interleukin-1 receptor accessory protein (IL1RAP). CAN14 is designed to target IL1RAP in combination with an undisclosed second target, aiming to either block or engage IL1RAP-related signaling pathways. While specific disease indications have not been publicly announced, the drug is part of a broader strategy to address unmet needs in oncology and autoimmune or inflammatory diseases. As of early 2026, the program remains in the preclinical stage, with candidate selection for CAN14 anticipated by the end of 2026.